Tris Pharma Launches ONYDA XR: A New ADHD Liquid Solution
Introduction of ONYDA XR in the U.S. Market
Tris Pharma, Inc., a dynamic biopharmaceutical company specializing in addressing ADHD and various neurological disorders, proudly announces the launch of ONYDA™ XR (clonidine hydrochloride) extended-release oral suspension. This innovative once-daily liquid medication recently received approval from the U.S. Food and Drug Administration (FDA). Designed specifically for pediatric patients aged six and older, ONYDA XR can be utilized as a standalone treatment or as an adjunct therapy alongside approved CNS stimulant medications.
Convenient Access for Patients
Healthcare providers can now prescribe ONYDA XR, which is readily available through national pharmaceutical wholesalers. Patients may fill their prescriptions at local pharmacies throughout the country, increasing accessibility to this valuable treatment option.
Importance of Non-Stimulant Options
As stated by Manesh Naidu, Tris Pharma's chief commercial officer, the introduction of ONYDA XR is particularly timely with the commencement of ADHD Awareness Month. This new medication stands as the first and only liquid non-stimulant therapy for ADHD in the U.S., providing an alternative for patients who may not respond adequately to traditional stimulant treatments or who encounter intolerable side effects. Tris Pharma aims to broaden access to this groundbreaking medication, with the goal of improving the quality of life for those affected by ADHD.
Innovative Drug-Delivery Technology
Developed with cutting-edge proprietary drug-delivery technology, ONYDA XR offers a once-a-day extended-release profile. This liquid formulation enables tailored dosing adjustments while ensuring ease of administration for patients who may struggle with pills. In a landscape where the prevalence of ADHD is on the rise, ONYDA XR fulfills the demand for diverse treatment options that cater to individual needs.
Expert Endorsements
Rakesh Jain, MD, MPH, a clinical professor at Texas Tech University School of Medicine – Permian Basin, emphasizes the significance of ONYDA XR. Patients who experience difficulties in pill ingestion or require a longer-acting solution now have a remedy specifically designed to meet those challenges. The introduction of ONYDA XR marks a noteworthy progression in customizing ADHD treatment options.
FDA Approval and Research Basis
The FDA's approval of ONYDA XR was based on comprehensive studies regarding clonidine hydrochloride extended-release tablets. This rigorous scrutiny underlines the safety and efficacy of the medication, ensuring that healthcare providers can confidently recommend it to their pediatric patients.
About Tris Pharma
Tris Pharma operates as an innovation-driven biopharmaceutical entity committed to revolutionizing the management of ADHD, pain, addiction, and central nervous system disorders. Their current portfolio showcases a variety of leading ADHD products, coupled with a promising pipeline of unique drug candidates that aim to reshape treatment paradigms. For further insights about their offerings, visit Tris Pharma's website.
Safety Considerations for ONYDA XR
Like any medication, ONYDA XR comes with specific safety information that prescribers and patients should be aware of. It is important to monitor blood pressure and heart rate in patients using ONYDA XR, particularly those with cardiovascular concerns or predispositions to low blood pressure. Additionally, healthcare providers should counsel patients on the potential for sedation and the importance of avoiding alcohol and other CNS depressants while using ONYDA XR.
Contraindications and Risks
The use of ONYDA XR is contraindicated in individuals with a history of hypersensitivity reactions to clonidine. Moreover, it is imperative to be cautious regarding other medications that may interact adversely, including tricyclic antidepressants and other sympatholytic drugs.
Conclusion
With the launch of ONYDA XR, Tris Pharma is forging a path towards enhanced treatment options for pediatric patients managing ADHD. This innovative liquid formulation not only represents a step forward in the versatility of ADHD therapies but also highlights Tris Pharma's dedication to addressing the unique and evolving needs of patients and healthcare providers alike.
Frequently Asked Questions
What is ONYDA XR?
ONYDA XR is a once-daily liquid medication approved for the treatment of ADHD in children six years and older.
How does ONYDA XR differ from traditional ADHD medications?
It is the first liquid non-stimulant ADHD medication approved in the U.S., offering an alternative for those who may not tolerate stimulant therapies.
What safety precautions should be taken with ONYDA XR?
Patients should be monitored for blood pressure changes and sedation, especially in those with existing cardiovascular concerns.
Can ONYDA XR be used with other ADHD treatments?
Yes, ONYDA XR can be used alone or as an adjunctive therapy to stimulant medications.
Where can patients obtain ONYDA XR?
Patients can fill their prescriptions for ONYDA XR at local pharmacies nationwide.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.